The Role of Epithelial Cytokines in CRSwNP

When irritants are inhaled, the nasal epithelium is compromised and epithelial cytokines are released. These cytokines initiate and perpetuate the inflammatory response that leads to CRSwNP. Biologic agents targeting the epithelium may be key in treatment; tezepelumab, a monoclonal antibody that blocks TSLP, has been shown to reduce nasal polyp size and improve symptoms such as congestion and sense of smell.
To learn more about chronic rhinosinusitis with nasal polyps and access the full activity, visit PeerView.com/AYT.